PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Assay, isolation and characterization of circulating immune complexes from serum of urinary bladder carcinoma patients
Article published in Urologia Polska 2005/58/1.

authors

Ryszard Gołda 1, Zbigniew Wolski 2, Małgorzata Wyszomirska-Gołda 1, Kazimierz Madaliński 3, Wojciech Jóźwicki 4, Jacek Michałkiewicz 1
1 Department of Immunology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
Head: Jacek Michałkiewicz
2 Department of Urology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
Head: Zbigniew Wolski
3 Department of Immunopathology, National Institute of Hygiene, Warsaw, Poland
Head: Kazimierz Madaliński
4 Department of Patomorphology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
Head: Renata Sujkowska

keywords

urinary bladder, bladder cancer, circulating immune complexes, atypical proteins

summary

introduction and aim of the study
Detection, measurement and characteristics of circulating immune complexes (CIC) present in the sera of cancer patients demonstrated both good and poor correlation with the progress of the disease. The aim of our study was to assess the significance of serum CIC levels and to estimate its atypical protein fractions in bladder cancer progression.
materials and methods
The levels as well as the characteristics of circulating immune complexes were estimated in the sera of 76 patients with bladder cancer (G-1, G-2, G-3 grades) by means of polyethylene glycol (PEG) precipitation test. The molecular weight of the CIC proteins was studied by SDS/PAGE.
results
The results were compared with the group of 45 healthy men. Elevated CIC levels were observed in 52.6% of the patients with urinary bladder cancer. No seropositivity for CIC was observed in the control group. An increase in the seropositivity for CIC was observed in the patients with highest grade bladder cancer: the proportion of seropositive patients in the group of patients with G-1 phase of the disease was 38.1%, in the G-2 group - 56.2%, and in the G-3 - 60.8 %. The CIC obtained from patients with bladder cancer contained proteins which were absent in the CIC from the sera of healthy subjects.
conclusions
For this reason, the determination and characterization of CIC levels can be helpful in both the diagnostic procedure and the analysis of atypical proteins forms generated by the neoplastic process. There is a need for further research to define the value of CIC atypical proteins analysis more precisely.

references

  1. Aziz M, Akhar S, Malik A: Evaluation of cell-mediated and circulating immune complexes as prognostic indicators in cancer patients. Cancer Detect Prev. 1998; 22; 87-99.
  2. Dass TK, Aziz M, Rattan A: Prognostic significance of circulating immune complexes in cancer patients. Jpn J Cancer Res 1991; 82; 1284-1294.
  3. Gendek-Kubiak H, Grzegorczyk J, Genek EG, Kowalski ML, Bener J: Preoperative levels of serum immunoglobulins, circulating immune complexes and complement proteins in patients with different types neoplasms. Arch Immunol Ther Exp 2001; 49; 89-95.
  4. Kobayashi K, Umeda T, Akaza H, Niijima T, Aikawa T, Tanimoto K: Circulating immune complexes in patients with bladder cancer and other malignancies of the urogenital tract. Urol Int 1984; 39; 232-235.
  5. Matchin AA, Smoliagin AI: A comparative evaluation of the immune status of patients with squamous-cell cancer of the oral mucosa at different stages of combined treatment. Stomatologiia (Mosk.) 2000; 3; 29-32.
  6. Sakai S, Kato N, Ito Y, et al: Detection of circulating immune complexes by polyethyleneglycol precipitation complement consumption test in urological malignant diseases. Hinyokika Kiy 1984; 30; 1611-1617.
  7. Tomasevic Z, Jelic S: Circulating immune complexes in advanced Hodgkin´s disease: qualitative analysis and prognostic significance. Arch Immunol Ther Exp 2000; 48; 195-200.
  8. Vlock DR, Schantz SP, Fisher SG, Savage HE, Carey TE, Wolf GT: Clinical correlates of circulating immune complexes and antibody reactivity in squamous cell carcinoma of the head and neck. J Clin Oncol 1993; 12; 2427-2433.
  9. Babaian RJ, Watson DA, Jones JM: Immune complexes in urine and serum of patients with bladder cancer. J Urol 1984; 131; 463- 466.
  10. Bhatti R, Shaw M and Ray P: Inhibition of sensitised leukocyte´s in vitro reactivity by circulating immune complexes in prostate cancer. Experiential 1987; 43; 916-917.
  11. Chester SJ, You-Pin Lim, Vezeridis MP, Hixon DC: Improved detection of the early stages of colon cancer by determining both free circulating and immune complex-bound antigens reactive with monoclonal antibody. Cancer Res 1994; 54; 3974-3978.
  12. Phillips TM: Immune complex assays: diagnostic and clinical application. Crit Rev Clin Lab Sci 1989; 27; 237-264.
  13. Skaarup P, Jensenius JC, Brandslund I, Svehag SE, Wolf H: Association of circulating immune complexes with glomerular proteinuria in patients with transitional cell carcinoma of the urinary bladder. Eur Urol 1984; 10; 249-253.
  14. Wong JM, Gupta RK, Morton DL: Serial determinations of melanoma tumour-associated antigen and antibody in-patients with stage I melanoma. Arch Surg 1986; 121; 1342.
  15. Mavligit GM, Stuckey S: Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer 1983; 52; 146.
  16. Bartoloni C, Guidi L, Pili R, et al: Assay, isolation and characterisation of immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients. Oncology 1993; 50; 27-34.
  17. Habal N, Gupta RK, Bilchik AJ, Jonson T, Morton DL: TA90-IC, a new marker for advanced colon cancer. Ann Surg Oncol 2000; 7; 352-356.
  18. Nelson MB, Nyhus JK, Oravecz-Wilson KI, Barbera-Guillem E: Tumour cells express Fc gamma RI which contributes to tumour cell growth and a metastatic phenotype. Neoplasia 2001; 3; 115-125.
  19. Theofilopoulos AN: Immune complexes in cancer. N Engl J Med 1982; 307; 208-1209.
  20. Wiederkehr F, Bueler MR, Vonderschmitt DJ: Chromatographic and electrophoretic studies of circulating immune complexes in plasma. J Chromatogr 1991; 566; 77-87.
  21. Digeon M, Laver M, Riza J, Bach JF: Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol. J Immunol Methods 1977; 16; 165-183.
  22. Madalinski K, Buczynska A, Heermann KH, Uy A, Gelich H: Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 1991; 84; 493-500.
  23. Gołda R, Wolski Z, Wyszomirska-Gołda M, Madaliński K, Michałkiewicz J: The presence and structure of circulating immune complexes in patients with prostate tumors. Med Sci Monit 2004; 10; 123-127.
  24. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227; 680-685.
  25. De Moreno MR, Smith JF, Smith RV: Silver staining of proteins in polyacrylamide gels: Increased sensitivity through a combined Coomassie blue-silver stain procedure. Anal Biochem 1985; 151; 466-470.
  26. Friedman RD: Comparison of four different silver-staining techniques for salivary protein detection in alkaline poliactrylamide gels. Anal Biochem 1982; 126; 346-349.

correspondence

Ryszard Gołda
Department of Immunology
The Ludwik Rydygier Collegium Medicum in Bydgoszcz
Nicolaus Copernicus University in Toruń
Maria Skłodowska-Curie Street 9, 85-095 Bydgoszcz, Poland
tel. (0... 52) 585 35 78
goldar@cm.umk.pl